Candonilimab

Generic Name: Candonilimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2394841-59-7

Unique Ingredient Identifier: 6FYG1DS4NW

Background: Cadonilimab is under investigation in clinical trial NCT04220307 (A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma).

Indication: 用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌患者的治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Phase 2

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Fruquintinib
Drug: Cadonilimab
Radiation: SBRT

First Posted Date: 2023-12-13

Last Posted Date: 2023-12-21

Lead Sponsor: Huazhong University of Science and Technology

Target Recruit Count: 40

Registration Number: NCT06168786

Locations: 🇨🇳
Huazhong University of Science and Technology, Wuhan, Hubei, China

Cadonilimab + FOLFOX Versus FOLFOX in the Neoadjuvant Treatment of pMMR/MSS Locally Advanced Colorectal Cancer

Phase 2

Recruiting

Conditions: Locally Advanced Colorectal Carcinoma

Interventions: Drug: Cadonilimab
Drug: FOLFOX regimen

First Posted Date: 2023-12-04

Last Posted Date: 2023-12-04

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 170

Registration Number: NCT06154538

Locations: 🇨🇳
Cancer Hospital/ National Cancer Center, Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer

Not yet recruiting

Conditions: Recurrent or Metastatic Cervical Cancer

Interventions: Drug: Cadonilimab

First Posted Date: 2023-12-04

Last Posted Date: 2023-12-04

Lead Sponsor: Gang Chen (101199)

Target Recruit Count: 670

Registration Number: NCT06155422

Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)

Phase 2

Recruiting

Conditions: Esophagus Cancer

Interventions: Drug: Cadonilimab
Drug: Paclitaxel and cisplatin
Radiation: intensity-modulated radiotherapy

First Posted Date: 2023-11-22

Last Posted Date: 2024-03-12

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 46

Registration Number: NCT06143748

Locations: 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China

Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer

Not yet recruiting

Conditions: Cervical Cancer

Interventions: Drug: Cadonilimab

First Posted Date: 2023-11-20

Last Posted Date: 2024-06-04

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 200

Registration Number: NCT06140589

Locations: 🇨🇳
No. 420 Fuma Road, Jin'an District, Fuzhou City, Fujian Province, Fuzhou, Fujian, China

A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Phase 2

Recruiting

Conditions: Muscle Invasive Bladder Carcinoma

Interventions: Drug: RC48-ADC
Drug: AK104

First Posted Date: 2023-10-10

Last Posted Date: 2023-10-10

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 36

Registration Number: NCT06074484

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer

Phase 2

Not yet recruiting

Conditions: Endometrial Cancer
Endometrial Adenocarcinoma

Interventions: Drug: Cadonilimab
Drug: Carboplatin
Drug: Cisplatin
Drug: Paclitaxel

First Posted Date: 2023-10-04

Last Posted Date: 2024-01-23

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 45

Registration Number: NCT06066216

AK104 Combined With I-125 Brachytherapy for Recurrent or Metastatic Cervical Cancer

Not yet recruiting

Conditions: Cervical Cancer

First Posted Date: 2023-10-02

Last Posted Date: 2023-10-02

Lead Sponsor: Peking University Third Hospital

Target Recruit Count: 18

Registration Number: NCT06062589

Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Phase 1

Recruiting

Conditions: Portal Vein Tumor Thrombus
Immune Checkpoint Inhibitors
Hepatocellular Carcinoma Non-resectable

Interventions: Drug: Cadonilimab
Radiation: Stereotactic radiotherapy
Drug: Renvatinib

First Posted Date: 2023-09-15

Last Posted Date: 2023-09-15

Lead Sponsor: First Affiliated Hospital of Guangxi Medical University

Target Recruit Count: 30

Registration Number: NCT06040177

Locations: 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Locally Advanced Operable

Interventions: Drug: Cadonilimab
Drug: Docetaxel
Drug: Cisplatin

First Posted Date: 2023-09-05

Last Posted Date: 2023-09-05

Lead Sponsor: Xuekui Liu

Target Recruit Count: 30

Registration Number: NCT06023875

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy